Sin-Ho Jung is a professor of biostatistics and bioinformatics at Duke University School of Medicine. He earned a PhD from the University of Wisconsin-Madison. His research interests include clinical trial design, survival analysis, longitudinal data analysis, clustered data analysis, ROC curve analysis, and microarray studies.
""Randomized Phase II Cancer Clinical Trials will be an invaluable source of information and reference for anyone interested in phase II cancer clinical trials, be it a graduate student, a biostatistics professor, or a cancer clinician in need of flexible designs and statistical analyses. … informative and interesting to read. The first of its kind, this book introduces the recent development of the promising randomized phase II trials. … This book has a very coherent structure and a legible style. … The author did an excellent job providing both contextual and technical details in a form that is both engaging and very readable. … a practical guidance book for cancer clinicians, as well as an excellent reference book for a more broad course, say, for example, clinical trials."" —Journal of the American Statistical Association, December 2014 ""… this book is very timely and it can help biostatisticians and oncologists design more elaborate cancer clinical trials. This book is well written and nicely organized to illustrate statistical concepts and methods in both single-arm and randomized phase II cancer clinical trials. … This book is certainly one of the best textbooks for a graduate-level clinical trial course in the biostatistics department. Also, oncologists with weak statistical background can easily understand the statistical concepts of the phase II cancer clinical trials since the author tries to explain the key concepts with many tables and figures instead of relying on equations."" —Biometrics, September 2014 ""… the book is unique in that it focuses solely on phase II cancer clinical trials with its emphasis on randomised trials. It goes far beyond what is covered on phase II clinical trials in cancer in books, for example, in Buyse et al. (1984) and more recently in Crowley & Hoering (2012) or Green et al. (2012). As such, it will definitely serve well as a reference for those involved in phase II cancer c